| 11/13/2008 | CVDDSS | DOV Pharmaceutical needs to find capital by December to keep clinical trial, operations going
|
| 11/7/2007 | CVDDSS | DOV Pharmaceutical says capital needs threaten going concern status
|
| 8/8/2007 | CVDDSS | DOV Pharmaceutical funding needs threaten going-concern status beyond Dec. 31
|
| 3/30/2007 | CVDDSS | DOV Pharmaceutical repays $2.5 million accelerated debentures; going concern status threatened
|
| 3/15/2007 | CVDDSS | DOV Pharmaceutical holders tender 96.4% of 2.5% debentures under exchange offer
|
| 3/8/2007 | CVDDSS | DOV Pharmaceutical modifies, extends exchange offer for 2.5% convertibles
|
| 3/6/2007 | CVDD | DOV Pharmaceutical extends 2.5% convertibles exchange offer to March 7
|
| 1/29/2007 | CVDDSS | DOV Pharmaceutical launches exchange offer for 2.5% convertibles
|
| 1/25/2007 | CVDDSS | DOV Pharmaceutical restructuring agreement includes exchange offer for 2.5% convertibles
|
| 1/3/2007 | CV | Market Commentary: Nabors falls in line on profit warning; Ford climbs with sales numbers; Sirius, XM marked higher on news
|
| 1/3/2007 | CVDDSS | DOV unable to buy back any 2.5% convertibles during required offer, causing event of default
|
| 11/9/2006 | BTCVDD | DOV Pharmaceutical to launch required 2.50% convertible buyback offer Friday
|
| 10/26/2006 | BTCVDD | DOV Pharmaceutical required 2.5% convertible buyback offer may force company to file bankruptcy
|
| 10/11/2006 | CV | Market Commentary: DOV gains on delisting speculation; Nabors slips amid buyout rumors; Harrah's lower with stock
|
| 8/9/2006 | BTCVDD | DOV must regain Nasdaq listing compliance to avoid 2.5% convertibles tender offer
|
| 7/27/2006 | BTCV | DOV Pharmaceutical exchanges $10 million 2.5% convertible debentures for stock
|
| 5/18/2006 | CV | Market Commentary: Enzon climbs, Nabors flat on debuts; American Axle gains on conversion expectations; DOV slides further
|
| 5/16/2006 | CV | Market Commentary: American Axle surges on possible loophole; DOV Pharmaceuticals falls, Sepracor gains on drug's rejection
|
| 4/25/2006 | CV | Market Commentary: Serologicals weakens on hedged basis; JetBlue, Level 3 gain on results; Dov falls on drug trial woes
|
| 2/3/2006 | CV | Market Commentary: UBS AG sets record with $2 billion of 18-month exchangeables; Amazon.com converts hold steady
|
| 9/12/2005 | CV | Market Commentary: Northwest drops as other airline convertibles trade mixed; software names see better bids
|
| 8/26/2005 | CV | Market Commentary: DOV Pharmaceutical convertibles tumble; Atherogenics adds; Agilent active on call news
|
| 5/26/2005 | CV | Market Commentary: Ford, GM better on short covering; airlines also firmer; techs rally but Computer Associates off after bell
|
| 1/12/2005 | CV | Market Commentary: Level 3 higher on job cuts; CenturyTel off; Kodak up; Advanced Micro rebounds
|
| 1/4/2005 | CV | DOV Pharmaceutical greenshoe exercised, raising convertibles to $80 million
|
| 12/17/2004 | CV | New Issue: DOV Pharmaceutical sells $65 million convertible to yield 2.5%, up 30%
|
| 12/17/2004 | CV | Market Commentary: IVAX reoffered at 98.5; BearingPoint up to 101.25; Charter up on M&A talk; PSEG soars on buyout buzz
|
| 12/16/2004 | CV | Market Commentary: Abgenix goes to 104; NRG climbs to 106.5; Gateway, BearingPoint up when-issued
|
| 12/16/2004 | CV | DOV Pharmaceutical prices $65 million convertibles to yield 2.5%, up 30%
|
| 12/15/2004 | CV | Market Commentary: Abgenix bid at 102.5 in gray market; NRG goes to 105; Gateway, Dover, BearingPoint rush market
|
